British Journal of Cancer 2011-Mar
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
L'enllaç es desa al porta-retalls
Paraules clau
Resum
BACKGROUND
This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).
METHODS
Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles.
RESULTS
Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.
CONCLUSIONS
The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.
